In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery

Table 5

Multiple comparison analysis showing the differences in the relative cell migration rate of human Tenon’s fibroblasts (HTFs) in each group.

Group	BVZ + 5-Fu	5-Fu	BVZ	BVZ + MMC	MMC	VEGF	Con
	value	value	value	value	value	value	value
BVZ + 5-Fu	—	0.001	<0.0001	0.066	0.099	<0.0001	<0.0001
5-Fu	0.001	—	0.001	0.019	<0.0001	<0.0001	<0.0001
BVZ	<0.0001	0.001	—	0.002	<0.0001	<0.0001	<0.0001
BVZ + MMC	0.066	0.019	0.002	—	0.027	<0.0001	<0.0001
MMC	0.099	<0.0001	<0.0001	0.027	—	<0.0001	<0.0001
VEGF	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	—	<0.0001
Con	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	—

Note. BVZ: bevacizumab; 5-Fu: 5-fluorouracil; MMC: mitomycin C; VEGF: vascular endothelial growth factor; Con: control.